The Company uses contract facilities that are registered with the FDA, have a track record of large-scale API manufacture, and have already invested in capital and equipment.
Reciprocal relationship from PPCB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from PPCB g…
In fiscal year 2025, the Company received a grant of A$42 thousand from the sale of Paxalisib to the Michael J Fox Foundation to explore the therapeutic potential of Paxalisib as a treatment for Park…
uation involved auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed. The primary procedures …
or the years ended 30 June 2025, 2024, and 2023, no contract milestones were met, therefore no revenue was recognized. License Agreement with Sovargen Co Ltd. In March 2024, the Company entered into …
Increases in manufacturing costs could adversely affect the Company’s future profitability if it was unable to pass all of the increased costs along to its customers.
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, …
al reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit inclu…
Kazia Therapeutics Limited Debt Obligations
Instrument
Description
Confidence
Evidence
KZIA-DEBT
Debt stack $70,677
90%
Market cache reports total debt of $70,677.
Kazia Therapeutics Limited Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kazia Therapeutics Limited.
Kazia Therapeutics Limited Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Kazia Therapeutics Limited.
